AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3914885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal PGF2 alpha (40 mg in tylose gel)
Number of subjects: 202
Study 3914885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal PGF2 alpha
Number of subjects: 202
Study 3914885 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 202
Study 29857776 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education plus eight group sessions of stress management and relaxation (DE + SMR)
Number of subjects: 55
Study 29857776 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education only (DE-only)
Number of subjects: 55
Study 27577237 — intervention group
Group type: EXPERIMENTAL
Intervention: PfAMA1-FVO vaccine (50 µg)
Number of subjects: 40
Study 27577237 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (tetanus toxoid)
Number of subjects: 40
Study 24388792 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day bowel preparation (fiber-free diet and 3 L of polyethylene glycol on day 0)
Number of subjects: 40
Study 24388792 — intervention group
Group type: COMPARATOR
Intervention: Two-day bowel preparation (liquid diet and 3 L of polyethylene glycol in the evening of day -1, and 1L of PEG in the early morning of day 0)
Number of subjects: 40
Study 24388792 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day bowel preparation
Number of subjects: 40
Study 24388792 — intervention group
Group type: COMPARATOR
Intervention: Two-day bowel preparation
Number of subjects: 40
Study 22139886 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + ablation of non-PV triggers (arm 1)
Number of subjects: 156
Study 22139886 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + ablation of non-PV triggers + empirical ablation at common non-PV AF trigger sites (arm 2)
Number of subjects: 156
Study 22139886 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + ablation of non-PV triggers + ablation of left atrial complex fractionated electrogram sites (arm 3)
Number of subjects: 156
Study 22139886 — intervention group
Group type: COMPARATOR
Intervention: Standard approach (PVI)
Number of subjects: 156
Study 20544810 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg pramipexole
Number of subjects: 535
Study 20544810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 18164462 — intervention group
Group type: EXPERIMENTAL
Intervention: Various nonsurgical interventions for CLBP; specific interventions not detailed.
Number of subjects: 0
Study 16168344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (n=218), with questionnaires sent 1, 6, and 12 months after screening
Number of subjects: 431
Study 16168344 — intervention group
Group type: COMPARATOR
Intervention: Limited follow-up (n=213), with a single questionnaire at 1 year
Number of subjects: 431
Study 12663319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (tailored nutrition counseling)
Number of subjects: 105
Study 12663319 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 10719133 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure biofeedback treatment (BF) once a week for a total of four sessions
Number of subjects: 38
Study 10719133 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure biofeedback treatment (BF)
Number of subjects: 38
Study 8646865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream, 0.05%, twice-daily (BID) application
Number of subjects: 238
Study 8646865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream, 0.05%, once-daily (QD) application
Number of subjects: 238
Study 8646865 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 238
Study 1906692 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (coronary arteriography with percutaneous angioplasty if feasible)
Number of subjects: 3339
Study 1906692 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg rt-PA
Number of subjects: 3339
Study 1906692 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravenous beta-blocker therapy
Number of subjects: 3339
Study 1906692 — intervention group
Group type: COMPARATOR
Intervention: 100 mg rt-PA
Number of subjects: 3339
Study 1906692 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (coronary arteriography for recurrent ischemia)
Number of subjects: 3339
Study 3994783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 mg daily, single administration)
Number of subjects: 0
Study 3994783 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate (300 mg daily, 3 administrations)
Number of subjects: 0
Study 3994783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 or 200 mg/day after 9 months)
Number of subjects: 0
Study 3994783 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate (400 mg/day after 9 months)
Number of subjects: 0
Study 29910048 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged event-free on day 3 (1,689 patients)
Number of subjects: 20410
Study 29910048 — intervention group
Group type: COMPARATOR
Intervention: Remained hospitalized at the end of day 3 (14,190 patients)
Number of subjects: 20410
Study 29910048 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged event-free on day 4 (1,706 patients)
Number of subjects: 20410
Study 29910048 — intervention group
Group type: COMPARATOR
Intervention: Remained hospitalized at the end of day 4 (11,628 patients)
Number of subjects: 20410
Study 26415029 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate skin‐to‐skin contact (ISSC) and breastfeeding in the operating room during cesarean section (C/S)
Number of subjects: 90
Study 26415029 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding 1 hour after cesarean section (C/S)
Number of subjects: 90
Study 24852255 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT) for 8 weeks, 1 day per week, 60-minute session duration
Number of subjects: 18
Study 24852255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional conditioning training)
Number of subjects: 18
Study 22339105 — intervention group
Group type: EXPERIMENTAL
Intervention: Far infrared rays (FIR) thermal therapy applied on acupoints ST37, ST38, ST39, ST40 from day 3 to day 5 post-surgery
Number of subjects: 41
Study 22339105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 41
Study 21519296 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 3% hypertonic saline (HTS)
Number of subjects: 8
Study 21519296 — intervention group
Group type: COMPARATOR
Intervention: Oral 3% hypertonic saline (HTS)
Number of subjects: 8
Study 18642381 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation-supported voice exercises (ES)
Number of subjects: 90
Study 18642381 — intervention group
Group type: COMPARATOR
Intervention: Voice exercise therapy (VE)
Number of subjects: 90
Study 16926331 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EBT) with an iridium 192 source, prescribed dose of 12 Gy at 3 mm from the source axis
Number of subjects: 102
Study 16926331 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA) plus EBT
Number of subjects: 102
Study 16926331 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) alone
Number of subjects: 102
Study 12907320 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded balloon distentions at the striated muscle segment
Number of subjects: 22
Study 12907320 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded balloon distentions at the smooth muscle segment
Number of subjects: 22
Study 11041310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin
Number of subjects: 37
Study 11041310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral opiates
Number of subjects: 37
Study 11041310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed regimens (intravenous heroin and oral opiates)
Number of subjects: 37
Study 11041310 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin maintenance
Number of subjects: 37
Study 11041310 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 37
Study 11041310 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatments (methadone maintenance, detoxification)
Number of subjects: 37
Study 8752162 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐TNF‐alpha and melphalan
Number of subjects: 24
Study 8752162 — intervention group
Group type: COMPARATOR
Intervention: melphalan only (control)
Number of subjects: 24
Study 1418021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injections of glycosaminoglycan polysulfate (GAGPS) plus basic conservative treatment
Number of subjects: 53
Study 1418021 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline injections plus basic conservative treatment
Number of subjects: 53
Study 1418021 — intervention group
Group type: COMPARATOR
Intervention: Basic conservative treatment alone (6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral NSAIDs)
Number of subjects: 53
Study 6323185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 25
Study 6323185 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 25
Study 30700349 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted phacoemulsification
Number of subjects: 94
Study 30700349 — intervention group
Group type: COMPARATOR
Intervention: Traditional phacoemulsification
Number of subjects: 94
Study 29733908 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scan staging (Yes)
Number of subjects: 598
Study 29733908 — intervention group
Group type: COMPARATOR
Intervention: Conventional staging (No)
Number of subjects: 598
Study 26602795 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 121
Study 26602795 — intervention group
Group type: COMPARATOR
Intervention: Saphenofemoral ligation and stripping (SFL/S)
Number of subjects: 121
Study 26602795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (EVLA and SFL/S)
Number of subjects: 121
Study 25062740 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller blade lifting the epiglottis
Number of subjects: 50
Study 25062740 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC blade lifting the tongue base
Number of subjects: 50
Study 25062740 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller blade lifting the tongue base
Number of subjects: 50
Study 23206200 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS intervention (five-session behavioral intervention)
Number of subjects: 827
Study 23206200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 827
Study 20197703 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fasting insulin levels
Number of subjects: 1353
Study 20197703 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher C-peptide levels
Number of subjects: 1353
Study 17656271 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine (30 mg in 1 mL saline)
Number of subjects: 35
Study 17656271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Mepivacaine and Morphine (30 mg mepivacaine and 1 mg morphine in 1 mL saline)
Number of subjects: 35
Study 17656271 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (1 mg in 1 mL saline)
Number of subjects: 35
Study 17656271 — intervention group
Group type: COMPARATOR
Intervention: Saline control (1 mL saline)
Number of subjects: 35
Study 16049199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 80
Study 11860043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pennebaker writing task
Number of subjects: 0
Study 11860043 — intervention group
Group type: COMPARATOR
Intervention: No-essay control conditions
Number of subjects: 0
Study 12811865 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7758179 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 200 mg IM given twice, 2 weeks apart
Number of subjects: 16
Study 7758179 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 16
Study 2321713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of lytic cocktail (0.05 ml/kg, max 2.0 ml)
Number of subjects: 51
Study 2321713 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of lytic cocktail (0.07 ml/kg, max 2.8 ml)
Number of subjects: 51
Study 6968567 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 35 868, dose: 2 mg kg‐1, injected over 30 s
Number of subjects: 10
Study 6968567 — intervention group
Group type: COMPARATOR
Intervention: Althesin, dose: 0.05 ml kg‐1, injected over 30 s
Number of subjects: 10
Study 6968567 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 35 868
Number of subjects: 10
Study 6968567 — intervention group
Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 10
Study 31940991 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-based chemotherapy
Number of subjects: 88
Study 31940991 — intervention group
Group type: COMPARATOR
Intervention: Non-paclitaxel-based chemotherapy
Number of subjects: 88
Study 31940991 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy for histological confirmation
Number of subjects: 88
Study 31940991 — intervention group
Group type: COMPARATOR
Intervention: Complete open staging surgery after laparoscopy
Number of subjects: 88
Study 31940991 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive washing cytology
Number of subjects: 88
Study 30732143 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice response system (IVRS) providing automatic calls in 3 categories: educational, medication adherence, and reminders.
Number of subjects: 120
Study 30732143 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 120
Study 27495950 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐reader iPAD
Number of subjects: 44
Study 27495950 — intervention group
Group type: COMPARATOR
Intervention: print
Number of subjects: 44
Study 25576240 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical exercise for 6 months (group I)
Number of subjects: 64
Study 23675422 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg/day
Number of subjects: 22
Study 23675422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21852281 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (WG)
Number of subjects: 21
Study 21852281 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study 19450038 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms of sharing needles among friends who inject
Number of subjects: 933
Study 19450038 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms of sharing cookers among friends who inject
Number of subjects: 933
Study 19450038 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms of sharing cotton among friends who inject
Number of subjects: 933
Study 19450038 — intervention group
Group type: EXPERIMENTAL
Intervention: Norms of sharing needles and front- or back-loading among friends who inject
Number of subjects: 933
Study 16470234 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-counseling intervention
Number of subjects: 267
Study 16470234 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 267
Study 12847161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left ATL
Number of subjects: 63
Study 12847161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right ATL
Number of subjects: 63
Study 12847161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left TLE
Number of subjects: 63
Study 12847161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right TLE
Number of subjects: 63
Study 12847161 — intervention group
Group type: COMPARATOR
Intervention: Healthy age- and education-matched controls
Number of subjects: 63
Study 10841953 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbipolar dissection (MBPD)
Number of subjects: 200
Study 9322987 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 1 (on awakening)
Number of subjects: 100
Study 9322987 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 2 (8 hours after awakening)
Number of subjects: 100
Study 9322987 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 3 (before bedtime)
Number of subjects: 100
Study 9322987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7679668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest interval of 2 weeks
Number of subjects: 284
Study 7679668 — intervention group
Group type: COMPARATOR
Intervention: Rest interval of 4 weeks
Number of subjects: 284
Study 7679668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients completing all three courses
Number of subjects: 284
Study 7679668 — intervention group
Group type: COMPARATOR
Intervention: Patients completing less than three courses
Number of subjects: 284
Study 7679668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Karnofsky Performance Status >= 80 and 2 week interval
Number of subjects: 284
Study 7679668 — intervention group
Group type: COMPARATOR
Intervention: Patients with Karnofsky Performance Status >= 80 and 4 week interval
Number of subjects: 284
Study 2942203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg per day alternating every two weeks with medroxyprogesterone acetate (MPA) 1,000 mg per day orally.
Number of subjects: 64
Study 2942203 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 30 mg per day and after relapse, high dosage of MPA alone.
Number of subjects: 64
Study 31729107 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10128
Study 29726596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural thrombotic events (IPTE)
Number of subjects: 1171
Study 29726596 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUITY minor bleeding
Number of subjects: 1171
Study 29726596 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUITY major bleeding
Number of subjects: 1171
Study 27941712 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with visual biofeedback
Number of subjects: 30
Study 27941712 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training without visual biofeedback (Control)
Number of subjects: 30
Study 25192980 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS combined with active venlafaxine (150‐225 mg/day)
Number of subjects: 170
Study 25192980 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS combined with placebo venlafaxine
Number of subjects: 170
Study 25192980 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS combined with active venlafaxine (150‐225 mg/day)
Number of subjects: 170
Study 22411689 — intervention group
Group type: EXPERIMENTAL
Intervention: DGLA-enriched oil (450 mg as free DGLA) for 4 weeks
Number of subjects: 0
Study 20865880 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 130
Study 20865880 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study 18179510 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired modeling
Number of subjects: 15
Study 18179510 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement
Number of subjects: 15
Study 18179510 — intervention group
Group type: COMPARATOR
Intervention: Close supervisor's position
Number of subjects: 15
Study 18179510 — intervention group
Group type: COMPARATOR
Intervention: Distant supervisor's position
Number of subjects: 15
Study 15086645 — intervention group
Group type: EXPERIMENTAL
Intervention: APN-directed discharge planning and home follow-up protocol (3 months)
Number of subjects: 239
Study 11949798 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1 (dentin bonding agent)
Number of subjects: 20
Study 11949798 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Coat (resin emulsion)
Number of subjects: 20
Study 9490250 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for Dupuytren contracture
Number of subjects: 47
Study 8004601 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography alone
Number of subjects: 4051
Study 8004601 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination and mammography
Number of subjects: 4051
Study 8004601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size <5 cm or no positive lymph nodes
Number of subjects: 4051
Study 8004601 — intervention group
Group type: EXPERIMENTAL
Intervention: Large tumors (≥5 cm)
Number of subjects: 4051
Study 3223639 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms.kg-1 morphine (group M)
Number of subjects: 24
Study 3223639 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6 micrograms.kg-1 buprenorphine (group B)
Number of subjects: 24
Study 3223639 — intervention group
Group type: COMPARATOR
Intervention: 0.1 ml.kg-1 normal saline placebo (group T)
Number of subjects: 24
Study 30115911 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg valproate
Number of subjects: 118
Study 30115911 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pregabalin
Number of subjects: 118
Study 30115911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 28508107 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine add-on treatment
Number of subjects: 448
Study 26226244 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (DCC), clamped 120 seconds after delivery
Number of subjects: 30
Study 26226244 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (DCC)
Number of subjects: 30
Study 26226244 — intervention group
Group type: COMPARATOR
Intervention: Early umbilical cord clamping (ECC), clamped <10 seconds after birth
Number of subjects: 30
Study 23047118 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9451 60 mg/day
Number of subjects: 41
Study 23047118 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9451 200 mg/day
Number of subjects: 41